New And Special Drugs

Pimjetmi (Pimicotinib) – TGCT | HongKong DengYue Medicine

Anxu (Rovadicitinib) – Myelofibrosis | HongKong DengYue Medicine

Goxblem (Bemiltenase alfa) – Hemophilia A/B | HongKong DengYue Medicine

Kardorisso (Asandeutertinib) – NSCLC | HongKong DengYue Medicine

Atled (Fanregratinib) – Intrahepatic Cholangiocarcinoma | HongKong DengYue Medicine

Redemplo (Plozasiran) – FCS | HongKong DengYue Medicine

Yizekang (Izalontamab Brengitecan) – NPC/ESCC | HongKong DengYue Medicine

Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
What Can We Offer You?

Generic drugs
Dedicated to providing high-quality, affordable medicines around the world

Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage

brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability

Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs

non-prescription drugs
Flagship OTC brand - approved and accepted by global standards

Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.

A Decade of Evolution in Non-Small Cell Lung Cancer Treatment Standards in China and the US (2016–2026)
Non-small cell lung cancer (NSCLC) accounts for the vast majority of lung cancer cases. Over the past decade, its treatment has gradually shifted from a

China Approves Imipenem-Cilastatin-Funobactam: First BL/BLI Combination Targeting Three Major Carbapenem-Resistant Bacterial Groups
On November 12, 2026, NMPA approved the marketing of imipenem-cilastatin-funobactam for injection, an innovative antibiotic independently developed by Evopoint Biosciences. The drug is indicated for

China Innovative Drugs on the Global Stage – Insights from BIO-Europe 2026
China is becoming a new focal point for global pharmaceutical partnerships. How is the European pharmaceutical industry discussing Chinese innovative drugs at BIO-Europe? The 32nd

FDA Approves Novel Chinese Drug Pimicotinib for Tenosynovial Giant Cell Tumor (TGCT)
On November 10, 2026, the U.S. Food and Drug Administration (FDA) approved pimicotinib (PIMJETMI®) for the treatment of adults with symptomatic tenosynovial giant cell tumor

Lymphoma CAR-T Therapy IM19 Approved in China for Relapsed or Refractory LBCL
On November 5, 2026, China’s National Medical Products Administration (NMPA) approved lymphoma CAR-T therapy IM19, developed by Imunopharm Technology, for adults with relapsed or refractory

20 FAQs About Medical Treatment in China for Foreigners
This article covers 20 FAQs about medical treatment in China for foreigners, offering practical guidance on healthcare procedures, medical resources, and travel arrangements for international

Medical Tourism in China: A Complete Guide for International Patients (2026)
This comprehensive guide to medical tourism in China covers major medical cities, leading hospitals, popular treatments, costs, and care processes for international patients. It also

Latest Innovative Drugs in China 2026
This article lists the latest innovative drugs in China 2026, including indications, pharmaceutical companies, and approval dates, updated through October 30, 2026. It is regularly
Fast And Safe Delivery

Global Transportation Express

Temperature-controlled Transport

Safe Transportation, GDP Compliant

